Saturday 17 October 2026 Export VCYT’s income statement to Excel — free account

Veracyte, Inc.

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

43.12 1.27 −2.86%

Follow VCYT

Alert me

Market cap: $3.6B
P/E: 29.9×
Fwd P/E: 45.1×
Dividend yield: —
F-score: 8/9
Altman Z: 21.08
Beneish M: −2.66
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Veracyte, Inc. (VCYT) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, Veracyte, Inc. (VCYT) trades at a P/E ratio of 29.9×. Over the past ten years it has ranged from 0.0× (December 2024) to 144× (January 2025); the current reading is higher than 86% of that period. That is below the Diagnostics & Research industry median of 35.6× and above the Healthcare sector median of 23.0×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/VCYT/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Veracyte, Inc. P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/VCYT/metrics/pe-ratio">Veracyte, Inc. (VCYT) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	50.1×	(59.50%)
FY2024	124×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	P/E ratio	Change
Jun 2026	40.8×	40.55%
Mar 2026	29.0×	(42.10%)
Dec 2025	50.1×	(43.06%)
Sep 2025	88.0×	13.98%
42 more quarters	Free account

Against its own ten years

Low 0.0× High 144×

Ten-year median 0.0×

Current reading's percentile 86

Company	P/E ratio
WGS GeneDx Holdings Corp. compare	n/m
RDNT RadNet, Inc. compare	n/m
NEO NeoGenomics, Inc. compare	n/m
GRAL GRAIL, Inc. compare	n/m
ADPT Adaptive Biotechnologies Corporation compare	n/m
CDNA CareDx, Inc. compare	29.7×
VCYT Veracyte, Inc.	29.9×
SHC Sotera Health Company compare	31.4×
BLLN BillionToOne, Inc. compare	95.0×
Diagnostics & Research industry median	35.6×
Healthcare sector median	23.0×
Market median	18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Veracyte, Inc. (VCYT) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on VCYT

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on VCYT

Stockrow Weekly